(Q38416045)

2 September 2017

title

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer (English)

1 reference

2 September 2017

1 reference

2

Bent Ejlertsen

1 reference

2 September 2017

Kirsten Vang Nielsen

1

1 reference

2 September 2017

Sven Müller

3

1 reference

2 September 2017

Susanne Møller

4

1 reference

2 September 2017

Birgitte B Rasmussen

5

1 reference

2 September 2017

Eva Balslev

6

1 reference

2 September 2017

Anne-Vibeke Lænkholm

7

1 reference

2 September 2017

Peer Christiansen

8

1 reference

2 September 2017

Henning T Mouridsen

9

1 reference

2 September 2017

language of work or name

English

0 references

publication date

17 June 2010

1 reference

Breast Cancer Research and Treatment

2 September 2017

published in

1 reference

2 September 2017

volume

127

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

345-355

1 reference

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Prognostic effect of estrogen receptor status across age in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Oestrogen receptor gene structure and function in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Gene amplification in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Genetic alterations of CCND1 and EMSY in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Novel patterns of genome rearrangement and their association with survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

ESR1 gene amplification in breast cancer: a common phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0984-Y

10.1007/S10549-010-0984-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1048953271

0 references

1 reference